This SPORE intends to build on M. D. Anderson's deep tradition of translational research and discovery in head and neck (HN) cancer therapy and chemoprevention to improve the basic understanding and clinical control of HN cancer. In response to our previous review, this revised application includes a new project, Project 1 (""""""""Intrinsic Apoptosis Phenotype and Susceptibility to Squamous Cell Carcinoma of the Oral Cavity""""""""), a significantly revised project (Project 3, previously numbered Project 2, """"""""Predictors of Resistance to Dual VEGFR/EGFR Targeted Therapy of Head and Neck Cancer"""""""") and two projects that were previously well-reviewed, """"""""Cancer Risk Assessment in Patients with Oral Premalignant Lesions: An Integrative Approach"""""""" (now numbered as Project 2), and """"""""Targeting EGFR and the IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma"""""""" (Project 4). We will investigate associations between genetic variants, apoptotic capacity phenotypes, and oral cancer risk (Project 1). We will assess the host susceptibility, global and specific molecular aberrations in oral premalignant lesions and epidemiologic factors build a model of risk for oral carcinogenesis (Project 2). We will investigate novel molecular profiling methods to identify signatures associated with resistance to an agent that co-targeting EGFR and VEGFR (Project 3), and we will investigate co-targeting EGFR and insulin-like growth factor 1 receptor (IGF-1R) (Project 4) in order to improve on the clinical benefit already achieved by EGFR inhibitors (e.g., cetuximab) in HN cancer patients. The translational expertise/resources of our biostatistics (e.g., comprehensive methodologies and models for assessing multiple biomarkers) and pathology cores (e.g., cutting-edge tissue banking) are unsurpassed in the world. The past trial activation and accrual record of this HN SPORE was the appropriate target of criticism in our previous review;thus, the SPORE leadership team has implemented several mechanisms to enhance the oversight, and thus activation and accrual, of our SPORE clinical trials, as detailed throughout this revised application. M. D. Anderson Cancer Center has reaffirmed its extraordinary commitment to this SPORE renewal. SPORE PI Dr. Lippman led a rigorous review of previous SPORE projects and relevant new science as we designed, refined, and selected projects for this revised renewal application. With substantive changes made to our application and the strengths of an exceptional leadership team and outstanding resources, we believe this HN SPORE application now reflects the most exceptional constellation of SPORE components and investigators that we could propose.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097007-07S1
Application #
7934187
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Nokta, Mostafa A
Project Start
2002-09-30
Project End
2013-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
7
Fiscal Year
2009
Total Cost
$100,000
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
(2018) Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 50:668-681
Jurkovic, Ines-Ana; Kocak-Uzel, Esengul; Mohamed, Abdallah Sherif Radwan et al. (2018) Dosimetric and Radiobiological Evaluation of Patient Setup Accuracy in Head-and-neck Radiotherapy Using Daily Computed Tomography-on-rails-based Corrections. J Med Phys 43:28-40
Huckins, L M; Hatzikotoulas, K; Southam, L et al. (2018) Investigation of common, low-frequency and rare genome-wide variation in anorexia nervosa. Mol Psychiatry 23:1169-1180
M. D. Anderson Cancer Center Head and Neck Quantitative Imaging Working Group (2018) Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. Sci Rep 8:1524
Gadhikar, Mayur A; Zhang, Jiexin; Shen, Li et al. (2018) CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78:781-797
Zhang, Tongwu; Choi, Jiyeon; Kovacs, Michael A et al. (2018) Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes. Genome Res 28:1621-1635
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Pinnix, Chelsea C; Ng, Andrea K; Dabaja, Bouthaina S et al. (2018) Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2:1334-1343
Kamal, Mona; Ng, Sweet Ping; Eraj, Salman A et al. (2018) Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol 79:1-8
Grossberg, Aaron J; Mohamed, Abdallah S R; Elhalawani, Hesham et al. (2018) Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. Sci Data 5:180173

Showing the most recent 10 out of 370 publications